BGLA Stock Chart & Stats
€9.63
-€0.19(-1.91%)
At close: 4:00 PM EST
€9.63
-€0.19(-1.91%)
Day’s Range― - ―
52-Week Range€8.38 - €12.32
Previous CloseN/A
Volume0.00
Average Volume (3M)28.00
Market Cap
€1.06B
Enterprise Value€11.38K
Total Cash (Recent Filing)€446.27M
Total Debt (Recent Filing)€0.00
Price to Earnings (P/E)33.7
Beta0.10
Next Earnings
Oct 28, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)3.43
Shares Outstanding98,497,170
10 Day Avg. Volume36
30 Day Avg. Volume28
Financial Highlights & Ratios
PEG Ratio-6.22
Price to Book (P/B)8.17
Price to Sales (P/S)6.98
P/FCF Ratio35.46
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.35
Revenue Forecast (FY)€150.86M
Bulls Say, Bears Say
Bulls Say
High ProfitabilitySustained high margins indicate structural product-level economics and pricing power in BioGaia's probiotic offerings. Durable gross and operating margins support reinvestment, consistent earnings quality, and resilience to cost swings, enabling long-term cash generation and shareholder returns.
Exceptionally Conservative Balance SheetNear-zero leverage and strong ROE give BioGaia lasting financial flexibility. The low debt profile reduces solvency risk, permits counter-cyclical investments or payouts, and preserves optionality for M&A or R&D spending without stressing cash flows over the next several months.
Proprietary Strain & Diversified Commercial ModelOwnership of patented L. reuteri strains and a mix of direct consumer sales plus partner licensing creates a durable competitive advantage. Intellectual property and B2B channels widen distribution, allow scalable royalty and supply income, and reduce need for heavy capex to expand reach.
Bears Say
Slowing Revenue GrowthThe clear deceleration from multi-year growth to near-single-digit then low-single-digit TTM growth signals maturing markets or tougher commercial execution. Persistent top-line slowdown can limit reinvestment capacity, reduce operating leverage benefits, and pressure long-term return expansion.
Weakening Free Cash Flow TrendAlthough absolute FCF remains healthy, the declining multi-year FCF trend erodes the margin of safety for dividends, buybacks, or M&A. If the weakening persists it could constrain strategic investments or force tougher capital-allocation choices despite still-strong profitability.
Balance Sheet Contraction / PayoutsA shrinking equity base or assets—potentially from elevated payouts—reduces financial headroom. Sustained balance-sheet contraction can limit capacity to fund growth initiatives or absorb shocks, making long-term expansion and flexibility more dependent on operational improvements.
BioGaia AB News
BGLA FAQ
What was BioGaia AB Class B’s price range in the past 12 months?
BioGaia AB Class B lowest stock price was €8.38 and its highest was €12.32 in the past 12 months.
What is BioGaia AB Class B’s market cap?
BioGaia AB Class B’s market cap is €1.06B.
When is BioGaia AB Class B’s upcoming earnings report date?
BioGaia AB Class B’s upcoming earnings report date is Oct 28, 2026 which is in 95 days.
How were BioGaia AB Class B’s earnings last quarter?
BioGaia AB Class B released its earnings results on Jul 17, 2026. The company reported €0.091 earnings per share for the quarter, missing the consensus estimate of €0.095 by -€0.004.
Is BioGaia AB Class B overvalued?
According to Wall Street analysts BioGaia AB Class B’s price is currently Overvalued.
Does BioGaia AB Class B pay dividends?
BioGaia AB Class B does not currently pay dividends.
What is BioGaia AB Class B’s EPS estimate?
BioGaia AB Class B’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does BioGaia AB Class B have?
BioGaia AB Class B has 98,497,170 shares outstanding.
What happened to BioGaia AB Class B’s price movement after its last earnings report?
BioGaia AB Class B reported an EPS of €0.091 in its last earnings report, missing expectations of €0.095. Following the earnings report the stock price went down -0.957%.
Which hedge fund is a major shareholder of BioGaia AB Class B?
Currently, no hedge funds are holding shares in DE:BGLA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
BioGaia AB Class B
BioGaia AB (publ), a Swedish enterprise founded in 1990 and headquartered in Stockholm, is dedicated to the worldwide development, marketing, and distribution of probiotic products renowned for their scientifically proven health advantages. The company operates through three primary divisions. Its Pediatrics segment offers various items such as drops, oral rehydration solutions, and gut health tablets, in addition to supplying cultures for integration into infant formula. The Adult Health segment provides gut health tablets and oral health lozenges, alongside furnishing cultures to licensees for use in dairy products. A third segment, "Other," specializes in packaging solutions. BioGaia's extensive product portfolio targets a range of health issues, including infantile colic and digestive health in children, antibiotic-associated and acute diarrhea, gingivitis, periodontal disease, general well-being, Helicobacter pylori bacterial infections (linked to gastric ulcers), and concerns related to low bone density. All of its offerings are sold exclusively under the BioGaia brand.